News

LePure Biotech was recognized by Legend Capital as one of the TOP 50 Healthcare Enterprises with Investment Values

LePure Biotech was recognized as one of the TOP 50 Healthcare Enterprises with Investment Values of Legend Captical. We are encouraged by the recognition of our investment performance in the healthcare industry.

Legend Capital was recognized as one of the TOP 30 Healthcare Investment Institutions and one of the TOP 15 Medical Device and Diagnosis Investment Institutions of the year 2021. We are delighted to share that Legend Capital and 19 of its portfolio companies were included in the 2021 China Healthcare Industry Investment and Financing Honor List, which was jointly issued by CHC (China Healthcare Consulting) and CITIC(China International Trust and Investment Corporation) Securities on May 26, 2022 and is an authoritative list in the medical and health field.

LePure Biotech was established in 2011. It pioneered localization of single-use solutions for biopharmaceutical industry in China.  LePure has comprehensive capabilities in R&D, manufacturing, and commercial operation.

In April 2001, Legend Capital was established as a fund manager under Legend Holdings, focusing on the early-stage VC and growth-stage PE investment. Since its establishment, Legend Capital has been adhereing to internationally accepted standards to create best practices in fund management and operation. With a proven track record of more than 20 years, it now has full experience in fund management and operation and has built an extensive partner ecosystem across the entire investment chain. Legend Capital goes the extra mile in delivering proactive value-added services to help portfolio companies drive innovations. We are committed to promoting China's industrial progress and social development, while securing high returns across various fields.

LePure Biotech was recognized by Legend Capital as one of the TOP 50 Healthcare Enterprises with Investment Values

Post time: May-26-2022